Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON39763
NL-OMON39763
Completed
N/A

CIP Pulsecath iVAC2L in High-Risk PCI patients - Pulsecath iVAC2

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites20 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionscoronair sclerose100110821000318410057166

Overview

Phase
N/A
Intervention
Not specified
Conditions
coronair sclerose
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
20
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\* Indicated for High\-Risk PCI, according to hospital standard procedure
  • •\* Indicated to have an IABP during the PCI, according to hospital standard procedure
  • •\* Expected duration of iVAC2L support: maximum 24 hours
  • •\* Patient older than 18 years
  • •\* Patient has signed the Informed Consent

Exclusion Criteria

  • •\* Aortic disease: ascending aortic aneurism, severe calcified aorta
  • •\* Aortic valvular disease: severe aortic valve stenosis, severe aortic valve insufficiency
  • •\* Aortic mechanical valve prosthesis
  • •\* Thrombus in left ventricle
  • •\* Intra ventricular septum defect
  • •\* Severe peripheral vascular disease
  • •\* No functioning right ventricle
  • •\* History of coagulation disorders
  • •\* Participation in another clinical study that may interfere with this study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
N/A
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular FunctionLeft Ventricular DysfunctionCoronary Artery Disease
NCT04763200Abiomed Inc.1,252
Not Yet Recruiting
N/A
Impella®-Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV TrialCoronary Artery Disease - narrowing/hardening of arteries that supply the heart with blood10011082
NL-OMON53537Abiomed, Inc.50
Withdrawn
N/A
Hemodynamic Effects Of Impella On Renal Circulation And Risk Of CA-AKI Among Patients Undergoing Protected PCIContrast-induced Acute Kidney Injury (CI-AKI)
NCT04928118Virginia Commonwealth University
Unknown
N/A
Recurrent Events After Percutaneous Coronary INterventio for ACSCoronary Artery DiseaseAcute Coronary Syndrome
NCT03675347A.O.U. Città della Salute e della Scienza2,000
Completed
N/A
Insertion of PICC With Intracavitary ECG NavigationLong-term Venous Access
NCT04444479University Hospital Ostrava450